MHRA Expands Casgevy Eligibility to Children Aged 5 and Older
Children aged 5 and older with severe sickle-cell disease or transfusion-dependent β-thalassemia can now be treated with Casgevy, according to the MHRA.
Children aged 5 and older with severe sickle-cell disease or transfusion-dependent β-thalassemia can now be treated with Casgevy, according to the MHRA.